| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015717A2 Tyrosine kinase inhibitors |
| 02/27/2003 | WO2003015704A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | WO2003015690A2 Method for treating primary insomnia |
| 02/27/2003 | WO2003015529A1 A process for tea flower |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002100862A3 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 02/27/2003 | WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 02/27/2003 | WO2002098413A3 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof |
| 02/27/2003 | WO2002098353A3 Compositions and methods for inhibiting bone resorption |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002096398A3 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 02/27/2003 | WO2002089740A3 Sulfonamides |
| 02/27/2003 | WO2002067869A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/27/2003 | WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002028379A3 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002022111A3 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 02/27/2003 | WO2002009674A3 Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030041337 Animal model for use in the diagnosis and treatment of diabetic phenotype |
| 02/27/2003 | US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection |
| 02/27/2003 | US20030040625 For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia |
| 02/27/2003 | US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof |
| 02/27/2003 | US20030040538 Novel substituted tricyclic compounds |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040530 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040510 Selective estrogen receptor modulators in combination with estrogens |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation |
| 02/27/2003 | US20030040490 Drugs containing combined active ingredients |
| 02/27/2003 | US20030040487 Polymer complexes of glucuronoglucanes |
| 02/27/2003 | US20030040483 Compounds with growth hormone releasing properties |
| 02/27/2003 | US20030040470 For therapy of hypercholesterolemia, viral infection |
| 02/27/2003 | US20030040464 Method of treating or preventing attention defecit hyperactivity disorder |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039740 Composition for enteral nutrition comprising fibres |
| 02/27/2003 | US20030039707 ATP synthesis activator |
| 02/27/2003 | US20030039687 Using Carbomer |
| 02/27/2003 | US20030039686 Increased absorption; aqueous solution containing fatty acid, or salt thereof |
| 02/27/2003 | US20030039666 Use of parasitic biological agents for prevention and control of autoimmune diseases |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039643 Investigation, diagnosis and treatment of subjects suspected of or suffering from alpha-N- acetylglucosaminidase deficiency |
| 02/27/2003 | US20030039627 Administering to the patient a therapeutically effective amount of an amine containing polymer |
| 02/27/2003 | US20030039626 Fat-binding polymers |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458068A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | CA2457644A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457164A1 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 02/27/2003 | CA2457142A1 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | CA2457037A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456843A1 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| 02/27/2003 | CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/27/2003 | CA2454083A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | CA2423025A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/26/2003 | EP1286165A2 Neuropeptide receptor and uses thereof |
| 02/26/2003 | EP1285914A1 Nr1h4 nuclear receptor binding compounds |
| 02/26/2003 | EP1285908A1 Substituted phenylpropionic acid derivatives |
| 02/26/2003 | EP1285664A2 Methods of increasing lean tissue mass using OB protein compositions |
| 02/26/2003 | EP1285660A1 Zinc-supplementary compositions for oral administration |
| 02/26/2003 | EP1285654A1 Autonomic controlling agents and health drinks and foods |
| 02/26/2003 | EP1285652A1 Novel fatty acid analogues for the treatment of hypertension |
| 02/26/2003 | EP1285590A1 Lipid blends |
| 02/26/2003 | EP1285269A2 Lipid uptake assays |
| 02/26/2003 | EP1285092A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1285061A1 Antisense modulation of pten expression |
| 02/26/2003 | EP1285002A2 REGULATING LIPID LEVELS VIA THE i ZMAX1 /i OR i HBM /i GENE |
| 02/26/2003 | EP1285000A2 Use of adnf for enhancing learning and memory |
| 02/26/2003 | EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators |
| 02/26/2003 | EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284958A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives |
| 02/26/2003 | EP1284753A2 Combination of growth hormone secretagogues and antidepressants |
| 02/26/2003 | EP1284747A2 Compositions and methods for achieving immune suppression |
| 02/26/2003 | EP1284739A1 Composition and method for intervening neuronal death using sulfasalazine |
| 02/26/2003 | EP1284734A1 Protein kinase inhibitors |
| 02/26/2003 | EP1284728A1 Pharmaceuticals for treating obesity |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284723A1 Compositions and therapies for hyperlipidaemia-associated disorders |
| 02/26/2003 | EP1237563A4 Nutritional composition, methods of producing said composition and methods of using said composition |